Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

Market Cap	14.47B -5.7%
Revenue (ttm)	5.48B +3.8%
Net Income	349.49M -46.0%
EPS	0.24 -46.0%
Shares Out	1.47B
PE Ratio	45.59
Forward PE	19.39
Dividend	0.15 (1.34%)
Ex-Dividend Date	n/a

Volume	3,819,741
Average Volume	4,144,967
Open	10.92
Previous Close	10.86
Day's Range	10.67 - 10.98
52-Week Range	10.30 - 14.34
Beta	0.44
RSI	36.46
Earnings Date	Mar 30, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,150
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002399

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.